NeuroQuest

Company Overview

Snapshot

Founded in January 2008, NeuroQuest operates with 1–10 employees and has raised $1.75M across three funding rounds from three investors. The company secured funding in May 2024 from the South Carolina Research Authority.

Business overview

NeuroQuest is a Health Tech & Life Sciences company focused on developing immuno-based blood tests for the early detection of Alzheimer's disease. Its core product, NeuroScreen™, is a novel blood-based diagnostic test leveraging the immune system's specific response to amyloid-beta accumulation. The company serves the medical technologies, diagnostics, and biotechnology sectors, targeting pharma companies, clinics, laboratories, and hospitals.

Strategic signal

In November 2022, NeuroQuest, in collaboration with AIBL, published findings on specific biomarkers for Alzheimer's disease, suggesting the potential for a blood-based screening tool. This development is significant for the diagnostics industry, as it indicates progress towards less invasive and earlier detection methods for Alzheimer's, offering a strong signal of the company's scientific validation and potential for market disruption.

Company Intelligence Q&A

What is NeuroQuest's primary focus?

NeuroQuest specializes in developing immuno-based blood tests for the early detection of Alzheimer's disease, utilizing its proprietary NeuroScreen™ technology.

When was NeuroQuest founded?

NeuroQuest was founded in January 2008.

Which organizations have invested in NeuroQuest?

NeuroQuest has received investment from organizations including The Trendlines Group and The InterTech Group.

What was a significant recent development for NeuroQuest?

In May 2024, NeuroQuest secured funding from the South Carolina Research Authority.

What was the outcome of NeuroQuest's collaborative study with AIBL?

In November 2022, a collaborative study by NeuroQuest and AIBL identified specific biomarkers for Alzheimer's, indicating the potential for a blood-based screening tool for the disease.